Isoprenylated flavonoids from Morus nigra and their PPAR γ agonistic activities.

Autor: Xu LJ; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China., Yu MH; Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, China., Huang CY; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China., Niu LX; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China., Wang YF; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China; Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, China., Wu CZ; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China., Yang PM; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China., Hu X; Innovation Center of Chinese Medicine, China State Institute of Pharmaceutical Industry, Shanghai 201203, China. Electronic address: xjtuyxhx@126.com.
Jazyk: angličtina
Zdroj: Fitoterapia [Fitoterapia] 2018 Jun; Vol. 127, pp. 109-114. Date of Electronic Publication: 2018 Feb 08.
DOI: 10.1016/j.fitote.2018.02.004
Abstrakt: A novel dihydroflavonol unprecedentedly with a prenyl group at C-2, nigragenon A (1), four new sanggenon-type flavonones, nigragenons B-E (2-5), along with six known isoprenylated flavonoids (6-11) were isolated from the twigs of Morus nigra. Their structures were elucidated through extensive analysis of spectroscopic data. Interestingly, compound 1 was the first reported biogenetic precursor of sanggenon-type flavanones and the biogenetic pathway from 1 to sanggenol F was proposed. The PPAR γ agonistic activity was investigated in HEK293 cells using dual luciferase reporter assay. Compounds 2, 4, 7, and 9 showed obvious agonistic activities on PPAR γ, and compound 2 was a potential PPAR γ partial agonist. Moreover, the preliminary structure-activity relationships for the tested compounds were discussed.
(Copyright © 2018 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: